ArticleIn vivo (Athens, Greece)

Bortezomib With High-dose Melphalan Conditioning Regimen in Newly Diagnosed Multiple Myeloma Patients: Long-term Follow-up.

Risa Nishiyama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.